Evoked otoacoustic emissions and pure tone threshold audiometry in patients receiving cisplatinum therapy.
Eight children and young adults with cancer were evaluated serially using pure tone audiometry as well as registration of click-evoked otoacoustic emissions (EOAE) 1 day prior to therapy as well as after various numbers of doses of cisplatinum. A reduction of EOAE-amplitudes following cisplatinum therapy was observed in all patients. This reduction tended to recover after the end of cisplatinum administration. Since EOAE are believed to result from cochlear bio-mechanical processes, the reduced emissions are interpreted as signs of cochlear dysfunction. We conclude, that EOAE testing may be a simple, non-invasive method that may detect early, transient functional impairment of hearing due to ototoxic agents such as cisplatinum, even in children. Further controlled trials are needed.
Zorowka
P G
PG
Department for Disorders of Communication, Johannes Gutenberg University, Mainz, FRG.
Schmitt
H J
HJ
Gutjahr
P
P
D000161:Acoustic Stimulation; D000293:Adolescent; D000328:Adult; D001301:Audiometry, Pure-Tone; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000009:adverse effects* / Q000627:therapeutic use; D015834:Cochlear Diseases / Q000139:chemically induced* / Q000175:diagnosis; D005072:Evoked Potentials, Auditory; D005260:Female; D006311:Hearing Disorders / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy; D017084:Otoacoustic Emissions, Spontaneous / Q000502:physiology*
D002945:Cisplatin